Suppr超能文献

早期卵巢癌手术:本文根据法国肿瘤学指南《上皮性卵巢癌患者的初始管理》起草,该指南由FRANCOGYN、CNGOF、SFOG、GINECO-ARCAGY在CNGOF的支持下制定,并得到了法国国家癌症研究所(INCa)的认可。

[Surgery in early-stage ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].

作者信息

Bolze P-A, Collinet P, Golfier F, Bourgin C

机构信息

Service de chirurgie gynécologique et oncologique, obstétrique, centre hospitalier universitaire Lyon Sud, université Claude-Bernard Lyon 1, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France.

Clinique de gynécologie, hôpital Jeanne-de-Flandre, centre hospitalier régional universitaire de Lille, 1, rue Eugène-Avinée, 59000 Lille, France.

出版信息

Gynecol Obstet Fertil Senol. 2019 Feb;47(2):168-179. doi: 10.1016/j.gofs.2018.12.007. Epub 2019 Jan 25.

Abstract

Early stage ovarian epithelial cancer (stage I according to the FIGO classification, i.e. limited to ovaries) affects 20% to 33% of patients with ovarian cancer. This chapter only describes data on these presumed early stages. The rate of occult epiploic metastases varies from 2% to 4%, and leads to over-staging in stage III A of 3% to 11% of patients. Performing an omentectomy does not result in a change in survival in this situation (NP4). The rate of appendix metastasis ranges from 0% to 26.7% (NP4). In the mucinous subtype, this rate can reach 53% if the appendix is macroscopically abnormal (NP2). The rate of positive peritoneal cytology ranges from 20.9% to 27%. Positive peritoneal cytology is responsible for over-staging of patients in 4.3% to 52% of cases and appears as a poor prognostic factor on survival (NP4). The rate of occult peritoneal metastases varies from 1.1% to 16%. Performing these peritoneal biopsies results in over-staging of 4% to 7.1% (NP4). In the management of ovarian cancers at a presumed early stage, it is recommended to perform: omentectomy, peritoneal biopsies, cytology, appendectomy (grade C). In case of incomplete or incomplete initial staging, restaging including omentectomy, peritoneal biopsies and appendectomy (if not explored) is recommended; especially in the absence of a reported indication of chemotherapy. The lymph node invasion rate ranges from 6.3% to 22%. It is 4.5% to 18% for stages I and 17.5% to 31% in stages II. Between 8.5% and 13% of patients with suspected early stage ovarian cancer are reclassified to stage IIIA1 following the completion of lymphadenectomy (NP3). Pelvic and lumbo-aortic lymphadenectomy improves the survival of patients with ovarian cancer at a presumptive early stage (NP2). Pelvic and lumbo-aortic lymphadenectomy is recommended for presumed early ovarian stages (grade B). In case of initial treatment of early-stage ovarian cancer without lymph node staging, restadification including lymphadenectomy is recommended; especially in the absence of a stated indication of chemotherapy (grade B). No studies have shown any laparoscopic disadvantage compared to laparotomy for feasibility, safety, or postoperative rehabilitation (NP3) in surgical staging of patients with early-stage ovarian cancer. For the initial surgical management of these patients, the choice between laparoscopy or laparotomy depends on local conditions (tumor size) and surgical expertise. If complete surgery without risk of tumor rupture is possible, the laparoscopic approach is preferred (grade C). In the opposite case, median laparotomy is recommended. As part of surgical restadification, the laparoscopic approach is recommended (grade C). Intraoperative tumor rupture leads to a decrease in disease free survival (hazard ratio=2.28) and overall survival (hazard ratio=3.79) (NP2). It is recommended that all precautions be taken to avoid perioperative ovarian tumor rupture, including the intraoperative decision of laparoconversion (grade C). There is no specific study to answer the question of the feasibility of a one-time or two-time surgery during an extemporane diagnosis of an early stage ovarian cancer. The high sensitivity and specificity of this extemporane examination in this situation makes it possible to consider a surgical management of staging during the same operating time.

摘要

早期卵巢上皮癌(根据国际妇产科联盟(FIGO)分类为I期,即局限于卵巢)占卵巢癌患者的20%至33%。本章仅描述这些假定早期阶段的数据。隐匿性网膜转移率为2%至4%,导致3%至11%的患者在III A期被过度分期。在这种情况下,进行网膜切除术不会导致生存率改变(NP4)。阑尾转移率为0%至26.7%(NP4)。在黏液性亚型中,如果阑尾在宏观上异常,该率可达到53%(NP2)。阳性腹腔细胞学率为20.9%至27%。阳性腹腔细胞学在4.3%至52%的病例中导致患者被过度分期,并且是生存的不良预后因素(NP4)。隐匿性腹膜转移率为1.1%至16%。进行这些腹膜活检会导致4%至7.1%的患者被过度分期(NP4)。在假定早期卵巢癌的管理中,建议进行:网膜切除术、腹膜活检、细胞学检查、阑尾切除术(C级)。如果初始分期不完整或不完全,建议进行包括网膜切除术、腹膜活检和阑尾切除术(如果未探查)的再次分期;特别是在没有报告化疗指征的情况下。淋巴结侵犯率为6.3%至22%。I期为4.5%至18%,II期为17.5%至31%。在完成淋巴结清扫术后,8.5%至13%的疑似早期卵巢癌患者被重新分类为III A1期(NP3)。盆腔和腹主动脉旁淋巴结清扫术可提高假定早期卵巢癌患者的生存率(NP2)。对于假定的早期卵巢阶段,建议进行盆腔和腹主动脉旁淋巴结清扫术(B级)。如果早期卵巢癌的初始治疗没有进行淋巴结分期,建议进行包括淋巴结清扫术的再次分期;特别是在没有明确化疗指征的情况下(B级)。没有研究表明在早期卵巢癌患者的手术分期中,与开腹手术相比,腹腔镜手术在可行性、安全性或术后康复方面有任何劣势(NP3)。对于这些患者的初始手术管理,腹腔镜手术或开腹手术的选择取决于局部情况(肿瘤大小)和手术专业知识。如果能够进行无肿瘤破裂风险的完整手术,首选腹腔镜手术方式(C级)。在相反的情况下,建议进行正中开腹手术。作为手术再次分期的一部分,建议采用腹腔镜手术方式(C级)。术中肿瘤破裂会导致无病生存期降低(风险比=2.28)和总生存期降低(风险比=3.79)(NP2)。建议采取一切预防措施以避免围手术期卵巢肿瘤破裂,包括术中决定转为开腹手术(C级)。没有具体研究来回答在早期卵巢癌即时诊断期间一次性或两次性手术的可行性问题。这种即时检查在这种情况下的高敏感性和特异性使得在同一手术时间内考虑进行分期的手术管理成为可能。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验